Antipsychotic Long-Acting Injections -

• Auteur(s) : Collectif
• Editeur : Oxford Univ Pr
• Langue : Anglais
• Parution : 01/12/2010
• Format : Moyen, de 350g à 1kg
• Nombre de pages : 268
• Expédition : 440
• Dimensions : 23.1 x 15.5 x 1.5

Biographie:
Dr Haddad graduated with honours degrees in both Medicine and Medical Biochemistry from the University of Manchester, UK. He received his MD for research regarding the relationship between affective disorder in cancer patients and their partners. He is a Consultant in Community Psychiatry in Salford and an Honorary Senior Lecturer at the University of Manchester. His clinical and research interests include the pharmacological treatment of affective disorders and schizophrenia. Dr Haddad has authored many publications including original research papers, review papers and book chapters. He was a member of the Development Group for the NICE Bipolar Guideline published in 2006 and the NICE Medicines Adherence Guideline published in 2009. He is an active member of the British Association of Psychopharmacology and has contributed to several of the Association's Guidelines. He is a member of the editorial board of the journal 'Human Psychopharmacology'. Tim Lambert is Professor and Head of Psychiatry at Concord Clinical School at the University of Sydney in Australia. He also holds an appointment as Head of Schizophrenia Treatment and Outcomes Research at the Brain & Mind Research Institute in Sydney. In addition, he fulfils clinical duties for the SSWAHS in Sydney as Director of the Centre of Excellence in Relapse Prevention in Psychosis and at the Concord Centre for Cardiometabolic Health in Psychosis. Professor Lambert has a portfolio of interests spanning clinical psychosis research, outcomes research, training, and education. His current interests focus on the clinical pharmacology of depot antipsychotics (first and second generation) and of the second-generation antipsychotics, particularly risk-benefit aspects and the applied clinical pharmacology of antipsychotic switching; physical comorbidities of psychotic disorders, especially metabolic syndrome; incomplete recovery, and services research (pharmacoepidemiology). Dr. Lauriello specializes in the diagnosis and treatment of psychotic disorders, most notably schizophrenia. In June 2009, he became only the third permanent chair of the MU department of psychiatry in its 50 year history. Dr. Lauriello also serves as the founding Executive Medical Director of the University of Missouri Psychiatric Center. Prior to coming to the University of Missouri Dr. Lauriello was the clinical Vice Chair at the University of New Mexico. There he directed the UNM Schizophrenia Research Group, which focused on clinical trials and neuroimaging. He was Executive Medical Director of the UNM Psychiatric Center for nearly a decade, and he served as a UNM site principal investigator for the Mental Illness and Neuroscience Discovery (MIND) Institute, a consortium of universities, schools of medicine, brain research institutions and laboratories in Minnesota, Massachusetts and New Mexico.

Sommaire:
1. Antipsychotic adherence in schizophrenia ; 2. Pharmacology of antipsychotic long-acting injections ; 3. Safety and adverse effects of antipsychotic long-acting injections ; 4. First generation (conventional) antipsychotic long-acting injections ; 5. Risperidone antipsychotic long-acting injection ; 6. Recently introduced antipsychotic long-acting injections: olanzapine pamoate and paliperidone palmitate ; 7. Antipsychotic long-acting injections in early intervention services ; 8. Attitudes to antipsychotic long-acting injections ; 9. Patient choice and improving the uptake of long-acting injectable medication ; 10. Prescribing patterns and determinants of use of antipsychotic long-acting injections: an international perspective ; 11. The role of antipsychotic long-acting Injections in current practice